Urogen Pharma (NASDAQ:URGN) Sees Unusually-High Trading Volume Following Analyst Upgrade

Urogen Pharma (NASDAQ:URGN - Get Free Report) shares saw an uptick in trading volume on Monday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. HC Wainwright now has a $50.00 price target on the stock. 2,166,518 shares were traded during mid-day trading, an increase of 119% from the previous session's volume of 989,570 shares.The stock last traded at $14.28 and had previously closed at $12.03.

URGN has been the topic of a number of other research reports. Oppenheimer decreased their target price on shares of Urogen Pharma from $36.00 to $10.00 and set an "outperform" rating on the stock in a research report on Tuesday, June 3rd. The Goldman Sachs Group cut their price objective on Urogen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Urogen Pharma in a research report on Thursday, June 12th. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. Finally, Guggenheim reissued a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Urogen Pharma presently has an average rating of "Buy" and a consensus price target of $32.86.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider now directly owns 153,378 shares of the company's stock, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.10% of the company's stock.

Institutional Trading of Urogen Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC raised its position in shares of Urogen Pharma by 94.3% during the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock worth $566,000 after acquiring an additional 24,839 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after purchasing an additional 2,983,368 shares during the last quarter. Parkman Healthcare Partners LLC increased its stake in Urogen Pharma by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock valued at $4,348,000 after purchasing an additional 23,292 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after purchasing an additional 1,653 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Urogen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after buying an additional 88,577 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Stock Up 12.3%

The firm's 50-day moving average price is $8.79 and its two-hundred day moving average price is $10.10. The company has a debt-to-equity ratio of 4.77, a quick ratio of 5.47 and a current ratio of 5.65. The firm has a market cap of $685.66 million, a PE ratio of -4.68 and a beta of 0.40.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. As a group, equities research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.